Travere Therapeutics CEO Eric Dube to step down in December

San Diego-based biopharmaceutical company Travere Therapeutics announced that CEO Eric Dube will resign on December 1, 2024, to focus on his health and family matters. The board of directors has selected Bradley L. Campbell as the new CEO, who will take over the role on the same date. Campbell, a veteran in the biopharmaceutical industry, previously held the positions of president and CEO at Amicus Therapeutics, which is now a subsidiary of BioMarin Pharmaceutical Inc. Dube will remain in his position until December 1, 2024, and continue as an executive advisor until February 15, 2027, to aid in the smooth transition.

Over the course of his tenure, Dube led Travere in securing regulatory approvals for IgA nephropathy and focal segmental glomerulosclerosis (FSGS) while expanding the company's pipeline and capabilities. Campbell boasts over 25 years of experience in the biopharmaceutical sector, with nearly 20 years spent at Amicus Therapeutics, rising through various leadership roles before becoming CEO in 2022.

Prior to this, Campbell had commercial and business development roles at Genzyme and Bristol-Myers Squibb. He currently serves on the Advisory Board of the Duke-Margolis Institute for Health Policy. Travere Therapeutics specializes in developing and delivering therapies for rare diseases, with a specific focus on rare kidney diseases.

The company's chairman, Gary Lyons, stated that the search for a new CEO was conducted comprehensively, aiming to find an individual with the necessary experience and leadership qualities to steer the company through its next phase.